We are excited to share with you this latest Porter & Co. Open Forum – a regular feature to allow readers to hear analysts from all our research advisories share ideas about markets and their portfolios. Below, we bring you a discussion between Distressed Investing editor Marty Fridson and editorial director Kim Iskyan. In this
Below we share with you the latest episode of Porter & Co. Open Forum – where readers ask our research analysts questions on a range of topics. Today, we bring you a discussion between Biotech Frontiers editor Erez Kalir and Porter Stansberry.
We are excited to share with you this latest Porter & Co. Open Forum – a regular feature through which analysts talk about their portfolios, key drivers of the economy, and top ideas, and address subscribers’ queries… Today, we bring you a discussion between Activist Investor editor Tom Carroll and publisher and CEO Kim Iskyan.
Below we share with you the latest episode of Porter & Co. Open Forum – where readers ask our research analysts questions on a range of topics. Today, we bring you a discussion between Biotech Frontiers editor Erez Kalir and CEO and publisher Kim Iskyan. In this conversation, Erez offers his current view on the
We are excited to share with you this latest Porter & Co. Open Forum – a monthly feature to allow readers to ask questions of analysts from all our research advisories. Below, we bring you a discussion between Distressed Investing editor Marty Fridson and publisher Kim Iskyan. In this “ask me anything” format, Marty answers
We are excited to share with you this latest Porter & Co. Open Forum – a new feature to allow readers to ask questions of analysts from all our research advisories. Below we bring you a discussion between Activist Investor editor Tom Carroll and publisher Kim Iskyan. In this “ask me anything” format, readers brought
Dear Readers, We are excited to share with you the first episode of Porter & Co. Open Forum – a new feature to allow readers to ask questions of analysts from all our research advisories. We kick it off with a discussion between Biotech Frontiers editor Erez Kalir and editorial director Kim Iskyan. In this “ask me anything” format,